No more typing reviews! Try our Samantha, our new voice AI agent.

What is Cymulate?

Featured Cymulate reviews

Cymulate Reviews Summary
Author infoRatingReview Summary
Head of Cyber Security at a financial services firm with 1,001-5,000 employees5.0Cymulate's endpoint testing feature greatly enhances our team's productivity and security posture, offering excellent reporting and ease of use. While initial setup consultancy is needed, our investment return has been substantial, surpassing traditional vulnerability management tools like Rapid7.
reviewer2340765 - PeerSpot reviewer
reviewer2340765
Head of Cyber Security at a financial services firm with 1,001-5,000 employees
Feb 6, 2024
An affordable solution that improves an organization’s security posture and provides excellent reporting capabilities

Cymulate mindshare

As of November 2026, the mindshare of Cymulate in the Continuous Threat Exposure Management (CTEM) category stands at 5.1%, down from 12.8% compared to the previous year, according to calculations based on PeerSpot user engagement data.
Continuous Threat Exposure Management (CTEM) Mindshare Distribution
ProductMindshare (%)
Cymulate5.1%
Wiz11.5%
XM Cyber7.9%
Other75.5%
Continuous Threat Exposure Management (CTEM)
 
 
Key learnings from peers

Valuable Features

Room for Improvement

ROI

Pricing

Popular Use Cases

Service and Support

Deployment

Scalability

Stability

Top industries

By visitors reading reviews
Financial Services Firm
15%
Manufacturing Company
9%
Comms Service Provider
9%
Computer Software Company
7%
Outsourcing Company
7%
Retailer
5%
Media Company
4%
Government
4%
University
3%
Insurance Company
3%
Hospitality Company
3%
Healthcare Company
3%
Educational Organization
3%
Marketing Services Firm
3%
Transportation Company
3%
Construction Company
2%
Wholesaler/Distributor
2%
Energy/Utilities Company
2%
Recreational Facilities/Services Company
2%
Performing Arts
2%
Legal Firm
2%
Real Estate/Law Firm
2%
Logistics Company
1%
Non Profit
1%
Maritime Company
1%
Consumer Goods Company
1%
Pharma/Biotech Company
1%

Compare Cymulate with alternative products

Learn more about Cymulate

Cymulate customers

Related questions